Navigation Links
Manufacturer Halts Production of Blood Thinner Heparin
Date:2/11/2008

Drug linked to hundreds of allergic reactions and possibly 4 deaths, FDA says

MONDAY, Feb. 11 (HealthDay News) -- Baxter HealthCare Corp., which produces half of the blood thinner heparin sold in the United States, said Monday that it was temporarily suspending production of its multi-dose injectable form of the drug following reports of serious allergic reactions and possibly four patient deaths.

The cause of the allergic reactions isn't known. It's also not clear how long production will be stopped. The one thing that is clear is that the stoppage could lead to a shortage of heparin, which is used to prevent blood clots in such patients as those undergoing kidney dialysis and heart surgery, U.S. health officials said.

Since the end of December, there have been about 350 reports of adverse reactions associated with Baxter's heparin product. This compares with less than 100 reports of adverse reactions in all of 2007, Dr. John Jenkins, director of the U.S. Food and Drug Administration Office of New Drugs at the Center for Drug Evaluation and Research, said during a Monday teleconference.

Most of the reactions have taken place at hemodialysis centers, almost exclusively involving patients receiving a "bolus dose," which is a high dose administered over a short period of time, the FDA said.

"While we have reports of four deaths at this time, it is not possible to establish a relationship between the deaths and the use of heparin," Jenkins said. "To date, a cause to the adverse events has not been identified."

Adverse reactions included difficulty breathing, nausea or vomiting, excessive sweating and falling blood pressure, which can lead to life-threatening shock. These reactions have been seen with as few as several thousand units per milliliter of heparin, and as much as 50,000 units per milliliter, Jenkins said.

Most of the reactions have taken place in patients receiving high doses of heparin before undergoing dialysis or heart surgery. The problem was first reported to the U.S. Centers for Disease Control and Prevention in January by the Missouri Department of Health and Senior Services, which had seen several cases in one pediatric hospital starting in November, the FDA said.

The CDC alerted the FDA and Baxter, which started a voluntary recall of the affected lots of heparin Jan. 17. Since that time, however, adverse reactions have been found in other lots of Baxter's multi-dose heparin, which led to Monday's suspension of production.

"FDA is currently collaborating with Baxter, the CDC and other experts to determine the root cause of the serious adverse events," Jenkins said. "Investigators and scientists are conducting inspections of all facilities and processes involved in the manufacture of Baxter's heparin. FDA investigators and scientists are also conducting tests of samples of Baxter's product."

Baxter's suspension of production of multi-dose vials of heparin could lead to a shortage of the drug, Jenkins said. "The FDA is working with other manufacturers of heparin to fill the void that will occur if the Baxter manufacturing suspension continues," he said.

It's not clear how long production will be stopped, so doses of Baxter's multi-dose heparin already in the hands of hospitals and clinics will not be recalled, Jenkins said.

"A recall would result in an immediate and severe shortage of this medically necessary drug. FDA has concluded that it is better for the public health to allow the Baxter multiple dose vials of heparin to remain in distribution," Jenkins said.

More than one million multiple-dose vials of heparin are sold each month in the United States.

A prepared statement released Monday by Baxter said: "Given the widespread use of this critical anticoagulant (frequently called a blood thinner) and the impact a product shortage would have on operating rooms, dialysis centers and other critical care areas, the removal of Baxter's heparin from the market would create more risk to the population of patients requiring heparin therapy than the increased potential for experiencing an adverse reaction."

Baxter, which is based in Deerfield, Ill., will continue to make its single dose vials of heparin. Adverse events like the ones associated with the multiple dose vials have been reported in a few cases when single dose vials were combined to give a single large dose to a patient, Jenkins said.

The other approved manufacturer of multiple dose vials of heparin, APP Pharmaceuticals of Schaumburg, Ill., is also being checked to see if there has been an increase in the number of adverse reactions with its product, Jenkins said. At this time, APP products have not been associated with these adverse events, he said.

Until the cause of the adverse reactions is known, the FDA is advising doctors to give large doses of heparin through intravenous infusion whenever possible. Doctors should also give the lowest dose at the slowest rate of infusion possible, and patients should be monitored for any sign of an adverse event, Jenkins said.

More information

For more on heparin, visit the U.S. National Library of Medicine.



SOURCES: Baxter HealthCare Corp., Deerfield, Ill., news release; Feb. 11, 2008, teleconference with John Jenkins, M.D., director, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration; Rockville, Md.


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. AUDIO From Medialink and the National Association of Margarine Manufacturers: Survey Finds Americans Unaware Some Fats Are Good for Heart Health
2. CardioDynamics Announces Strategic Alliance With Leading Medical Equipment Manufacturer in India
3. Patient Lift Manufacturer, Medcare Products, Obtains Women-Owned Certification
4. PCMA Statement on New Average Manufacturer Price (AMP) Legislation
5. Visiprise Launches Podcast Series with AMR to Support Medical Device Manufacturers
6. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
7. Experimental Vaccine Halts Prostate Cancer in Mice
8. Scripps research scientists find new genetic mutation that halts the development of lupus
9. Photo: New Data Show Gleevec(R) Halts Progression to Advanced Stages of Life-Threatening Form of Leukemia in Sixth Year of Treatment
10. Two Little Hands Productions, Creators of Popular Childrens TV Series Signing Time, Debuts Second Season at This Years Toy Fair 2008
11. Elephant Ensemble Theater Brings New Production to Bronx Hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... St. Louis, Missouri (PRWEB) , ... February 10, ... ... 11-14, 2016, in San Diego, will bring together more than 200 of the ... in healthcare for the future. , “The true benefit of the Forum is ...
(Date:2/10/2016)... ... 10, 2016 , ... AHRA: The Association for Medical Imaging ... Fox will serve as keynote speaker at the organization’s 2016 Spring Conference. Fox’s ... more effectively communicate with their own organizational staff and leadership. , “I ...
(Date:2/10/2016)... ... February 10, 2016 , ... Everseat has joined the award-winning ... to physicians. The integration will enable Allscripts users to post open appointments to ... mobile app. , The partnership gives Everseat substantial added power to help Allscripts ...
(Date:2/10/2016)... ... February 10, 2016 , ... The recreational use of marijuana has been ... still face a lot of restrictions as to where they can smoke pot. ... use” and that cannabis “may not be consumed openly or publicly.” , Given the ...
(Date:2/10/2016)... ... February 09, 2016 , ... According to a recent article published ... number of patients under the age of 30. According to Southern California based medical ... and may indicate an overall shift in the rapidly growing social acceptance of cosmetic ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , February 10, 2016 ... new market research report "Pharmaceutical Packaging Equipment Market by ... Labeling & Serialization), by Product Type (Tablet, Powder, Cream, ... published by MarketsandMarkets, studies the global market during the forecast ... to grow at a CAGR of 6.9% during the ...
(Date:2/10/2016)... On Tuesday, February 9th, the U.S. ... its Arthritis Advisory Committee to discuss Celltrion,s ... Johnson,s Remicade and most likely the second ... The Biologics Prescribers Collaborative (BPC) along with ... Patient Access, American Association of Clinical Endocrinologists, ...
(Date:2/10/2016)... 10, 2016 --> ... Therapeutics and Companion Diagnostic Market to 2019 - ... Environment" research report indicates that the core personalized ... by 2020 growing at a CAGR of 8.74%. ... and targeted therapeutics and is dominated by oncology, ...
Breaking Medicine Technology: